News

UroToday20h
ASCO 2025: Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cancer: Results of the SUNNIFORECAST Trial and Potential Role of the CPS Score and Tumor Nephrectomy
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
UroToday20h
ASCO 2025: Navigating the Crossroads: Evolving Paradigms in Perioperative Management of Muscle-Invasive Bladder Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the session Advancing Perioperative Treatment Options for ...
UroToday22h
ASCO 2025: Clonal Hematopoiesis in Participants with mCRPC Receiving 177Lu-PSMA-617 or Cabazitaxel: An Exploratory Post-Hoc Analysis of a Randomized Phase II Trial (TheraP ...
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer rapid oral abstract session and a presentation by Asli Munzur discussing an exploratory post-hoc analysis of TheraP assessing ...
UroToday22h
ASCO 2025: CA209-8TY Trial, a Randomized Phase 2 Trial of Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in mCRPC
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer rapid oral abstract session and a presentation by Dr. Rikke Eefsen discussing the CA209-8TY trial, a randomized phase 2 trial of ...
UroToday22h
ASCO 2025: Association of Circulating Immune and Metabolic Markers with Clinical Outcomes in the ENZAMET Trial (ANZUP 1304)
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...